GRIMES & Co WEALTH MANAGEMENT LLC Has $6.31 Million Stake in Novo Nordisk A/S $NVO

GRIMES & Co WEALTH MANAGEMENT LLC lessened its position in Novo Nordisk A/S (NYSE:NVO) by 9.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,752 shares of the company’s stock after selling 11,604 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Novo Nordisk A/S were worth $6,312,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Jennison Associates LLC lifted its position in shares of Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after buying an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Kingstone Capital Partners Texas LLC raised its position in shares of Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the period. Sustainable Growth Advisers LP boosted its holdings in shares of Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the period. Finally, State Street Corp grew its stake in Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after buying an additional 47,430 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. oral Wegovy rollout broadens commercial reach: Novo has launched its oral GLP‑1 (the “Wegovy Pill”) across a wide pharmacy network, making it the first oral weight‑loss GLP‑1 widely available in the U.S.; that distribution scale supports faster adoption and incremental sales versus an injection‑only offering. Read More.
• Positive Sentiment: Management sees a bigger oral market long term: Novo executives now expect oral GLP‑1 pills to capture over one‑third of the GLP‑1 market by 2030, implying a larger addressable market and more diverse revenue mix than previously modeled. That raises longer‑term revenue potential and reduces single‑product concentration risk. Read More.
• Positive Sentiment: Behavioral/health spillovers bolster product narrative: Research linking GLP‑1 receptor agonists to lower household spending on alcohol and tobacco supports a broader public‑health and societal value story that can aid payer conversations and public acceptance. Read More.
• Neutral Sentiment: Unusual options activity signals trader interest but not direction: Elevated/options flows show speculative positioning or hedging ahead of catalysts (sales data, guidance, regulation); could increase volatility in the short term without indicating a definitive fundamental shift. Read More.
• Neutral Sentiment: Increased analyst and fund attention raises visibility: Coverage from Fundsmith, Zacks and healthcare ETF narratives is driving investor focus on NVO (both positive for liquidity and sentiment but mixed on valuation). Monitor earnings/sales prints and guidance for conviction. Read More.
• Negative Sentiment: Compounded GLP‑1s pose a near‑term demand and pricing risk: CEO Mike Doustdar warned up to ~1.5M U.S. patients may be using compounded (unapproved, cheaper) GLP‑1 alternatives — that substitution can blunt uptake of branded products and pressure pricing if regulators or payers don’t constrain the compounding market. Read More.
• Negative Sentiment: Analyst caution on valuation and execution: Several commentaries urge caution despite investor confidence — potential overextension in the stock, reliance on continued rapid adoption, and execution risk around pharmacy rollout and payer coverage could cap upside. Read More.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $59.83 on Tuesday. The business has a fifty day moving average price of $49.87 and a two-hundred day moving average price of $55.15. The stock has a market capitalization of $267.12 billion, a PE ratio of 17.39 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Finally, Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.